Eloralintide
Sources
publication, as of 2025-11-06Stale
https://pubmed.ncbi.nlm.nih.gov/41207310/
Eloralintide is a novel, selective amylin receptor agonist. Participants received once-per-week subcutaneous injections. The mean percent change in bodyweight from baseline after 48 weeks (efficacy estimand) was -9% (1 mg), -12% (3 mg), -18% (6 mg), and -20% (9 mg), compared with -0.4% in the placebo group.
Lancet 2025;406:2631-2643, PMID 41207310, NCT06230523, abstract
registry, as of 2026-06-24Stale
https://clinicaltrials.gov/study/NCT06230523
Protocol section, NCT06230523, last update posted 2026-06-24
registry, as of 2026-09-22Stale
https://clinicaltrials.gov/study/NCT07321886
Protocol section, NCT07321886 ENLIGHTEN-1, last update posted 2026-09-22
registry, as of 2026-11-03
https://clinicaltrials.gov/study/NCT07900633
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 3000. Conditions Obesity; Overweight; Cardiovascular Diseases; Diabetes Mellitus, Type 2. The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.
ClinicalTrials.gov NCT07900633 protocol and results modules
registry, as of 2026-11-04
https://clinicaltrials.gov/study/NCT07282600
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes. Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 1035. Conditions Overweight; Obesity. The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
ClinicalTrials.gov NCT07282600 protocol and results modules
registry, as of 2026-11-04
https://clinicaltrials.gov/study/NCT07392190
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin. Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 900. Conditions Overweight; Obesity. The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last abo
ClinicalTrials.gov NCT07392190 protocol and results modules
registry, as of 2026-11-04
https://clinicaltrials.gov/study/NCT07353931
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight. Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 900. Conditions Osteoarthritis; Overweight or Obesity. The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the
ClinicalTrials.gov NCT07353931 protocol and results modules
registry, as of 2026-11-04
https://clinicaltrials.gov/study/NCT07369011
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight. Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 800. Conditions Sleep Apnea, Obstructive; Obesity; Overweight. The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will inclu
ClinicalTrials.gov NCT07369011 protocol and results modules
registry, as of 2026-10-08Stale
https://clinicaltrials.gov/study/NCT07589608
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight. Overall status RECRUITING. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 400. Conditions Overweight; Obesity. The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes.
ClinicalTrials.gov NCT07589608 protocol and results modules
registry, as of 2026-10-09Stale
https://clinicaltrials.gov/study/NCT07215559
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 200. Conditions Obesity; Overweight; Diabetes Mellitus, Type 2. The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.
ClinicalTrials.gov NCT07215559 protocol and results modules
registry, as of 2026-07-16Stale
https://clinicaltrials.gov/study/NCT07665879
A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity. Overall status RECRUITING. Phases PHASE1. Lead sponsor Eli Lilly and Company. Enrollment 115. Conditions Overweight; Obesity. The main purpose of the study is to measure and compare the effects of eloralintide and placebo on insulin sensitivity (how your body responds to insulin), metabolic health (things like sugar and cholesterol), and body weight in participants with obesity or overweight. For each p
ClinicalTrials.gov NCT07665879 protocol and results modules
registry, as of 2026-08-14Stale
https://clinicaltrials.gov/study/NCT07765511
A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes. Overall status NOT_YET_RECRUITING. Phases PHASE1. Lead sponsor Eli Lilly and Company. Enrollment 60. Conditions Obesity; Overweight. The main purpose of this study is to assess how well macupatide, when dosed alone and in combination with eloralintide, is tolerated and what side effects may occur in participants with obesity or overweight without Type 2 diabetes. Blood tests will be performed to investigate ho
ClinicalTrials.gov NCT07765511 protocol and results modules
registry, as of 2026-08-20Stale
https://clinicaltrials.gov/study/NCT07738614
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight. Overall status RECRUITING. Phases PHASE1. Lead sponsor Eli Lilly and Company. Enrollment 56. Conditions Obesity; Overweight. The main purpose of this study is to find out how significantly Eloralintide slows stomach emptying in participants who are overweight or obese. For each participant, the study will last approximately 21 weeks and will include 2 overnight stays in the clinical research unit (CRU)
ClinicalTrials.gov NCT07738614 protocol and results modules
registry, as of 2026-10-08Stale
https://clinicaltrials.gov/study/NCT07808060
A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight. Overall status RECRUITING. Phases PHASE1. Lead sponsor Eli Lilly and Company. Enrollment 34. Conditions Obesity; Overweight. The main purpose of this study is to evaluate how eloralintide (LY3841136) effects the way the body processes oral contraceptive in female participants with obesity or overweight. For each participant, the study will last about 8 months and will include 3 stays in the Clinical Re
ClinicalTrials.gov NCT07808060 protocol and results modules
registry, as of 2025-11-19Stale
https://clinicaltrials.gov/study/NCT06916091
A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight. Overall status COMPLETED. Phases PHASE1. Lead sponsor Eli Lilly and Company. Enrollment 30. Conditions Obesity; Overweight. The purpose of this study is to evaluate how well Eloralintide (LY3841136) is tolerated and what side effects may occur in overweight and obese Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check h
ClinicalTrials.gov NCT06916091 protocol and results modules